MedTech’s New Normal: More Regulatory, Pricing Pressures And Challenging Financing Climate
This article was originally published in The Gray Sheet
Executive Summary
Sustaining innovation in the current policy and financing environment may require new strategies from device companies focused not just on developing new products but on expanding into new kinds of offerings, including services and “holistic” solutions, Ernst & Young concludes in a recent report.You may also be interested in...
MedTech M&A Surge Continues In 2011 Following 95% Jump In 2010
Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: